Telmisartan vs. Perindopril in Mild-Moderate Alzheimer's Disease Patients
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 240
Summary
- Conditions
- Alzheimer's Disease
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
This study uses a simple validated measure of brain atrophy as a surrogate marker in a repurposing effort that could recast an antihypertensive medication as a cognitive enhancer/neuroprotective agent and possibly as a drug of choice for Alzheimer patients and patients at risk for AD. If the proof o...
This study uses a simple validated measure of brain atrophy as a surrogate marker in a repurposing effort that could recast an antihypertensive medication as a cognitive enhancer/neuroprotective agent and possibly as a drug of choice for Alzheimer patients and patients at risk for AD. If the proof of concept result is positive, a larger study would be warranted with potential practice-changing impact.
Tracking Information
- NCT #
- NCT02085265
- Collaborators
- Alzheimer's Drug Discovery Foundation
- Weston Brain Institute
- Investigators
- Principal Investigator: Sandra Black, MD Sunnybrook Health Sciences Centre Principal Investigator: Krista Lanctot, PhD Sunnybrook Research Institute
Get Well Soon